DnB Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

DnB Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.43M	Buy	19,060 +4,222	+28%	+$333K	0.01%	611
2025 Q4	$1.17M	Buy	14,838 +5,530	+59%	+$416K	﹤0.01%	629
2025 Q3	$609K	Sell	9,308 -2,963	-24%	-$145K	﹤0.01%	661
2025 Q2	$485K	Buy	+12,271	New	+$402K	﹤0.01%	652
2021 Q2	–	Sell	-56,658	Closed	-$2.55M	–	641
2021 Q1	$2.55M	Buy	56,658 +32,277	+132%	+$1.8M	0.02%	489
2020 Q4	$1.38M	Buy	24,381 +9,459	+63%	+$471K	0.01%	528
2020 Q3	$708K	Hold	14,922	–	–	0.01%	561
2020 Q2	$880K	Buy	14,922 +1,696	+13%	+$94.3K	0.01%	525
2020 Q1	$625K	Sell	13,226 -2,663	-17%	-$148K	0.01%	548
2019 Q4	$960K	Buy	15,889 +1,600	+11%	+$95.3K	0.01%	584
2019 Q3	$856K	Buy	14,289 +721	+5%	+$47K	0.01%	564
2019 Q2	$872K	Buy	+13,568	New	+$959K	0.01%	558

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DnB Asset Management's IONS Position: Q1 2026 in Review

DnB Asset Management increased its Ionis Pharmaceuticals (IONS) stake by 28% in Q1 2026, buying an estimated $333K and bringing the position to 19,060 shares worth $1.43M. The position accounts for 0.01% of the portfolio, ranked #611.

DnB Asset Management first reported a position in IONS in Q2 2019 and has held it in 12 quarters since. The position peaked at $2.55M in Q1 2021. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

DnB Asset Management held 19,060 shares of Ionis Pharmaceuticals worth $1.43M as of Q1 2026.
DnB Asset Management bought 4,222 Ionis Pharmaceuticals shares in Q1 2026, an estimated $333K.
Ionis Pharmaceuticals made up 0.01% of DnB Asset Management's portfolio in Q1 2026, its #611 holding.
DnB Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2019 and has held it in 12 quarters since.
DnB Asset Management's Ionis Pharmaceuticals position peaked at $2.55M in Q1 2021.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.